Furthermore, CLDN18 is correlated with worse patient prognosis in CRC, GC, and PC as well as being indicated as a biomarker for GC progression, while CLDN2 is demonstrated as a promising target in the treatment of CRC patients. The gene discussed is CLDN18; the disease is colorectal carcinoma.